Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P23416

UPID:
GLRA2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P23416; A8K0J6; B2R6I8; B7Z4F5; J3KQ59; Q53YX7; Q6ICQ0; Q99862

BACKGROUND:
Glycine receptor subunit alpha-2, a key component of inhibitory synapses, regulates neuronal excitability through chloride ion flux. This receptor's ability to respond to various ligands, including glycine and ethanol, and its role in synaptic plasticity, positions it as a critical modulator of brain function and behavior.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Glycine receptor subunit alpha-2 could open doors to potential therapeutic strategies for treating conditions like Intellectual developmental disorder, X-linked, syndromic, Pilorge type, characterized by significant neurological and behavioral abnormalities. Targeting this receptor may offer new avenues for intervention in such disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.